A Phase 2, Open-label, Multinational Study to Evaluate the Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome) Who Have Limited Ambulation
Phase of Trial: Phase II
Latest Information Update: 01 Feb 2017
At a glance
- Drugs Elosulfase alfa (Primary)
- Indications Mucopolysaccharidosis IV
- Focus Therapeutic Use
- Sponsors BioMarin Pharmaceutical
- 29 Feb 2016 Data from this trial will be presented at the 12th Annual WORLDSymposium, according to a BioMarin media release.
- 31 Jan 2015 New source identified and integrated (European Clinical Trials Database record: EudraCT2011-005703-33)
- 07 Dec 2014 Status changed from active, no longer recruiting to discontinued,as reported by ClinicalTrials.gov.